Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy

study id #: NCT03067831

condition: Duchenne Muscular Dystrophy

status: recruiting

This study is single arm, single center trial to study the safety and efficacy of bone marrow-derived autologous specific populations of stem cells and mesenchymal stem cells for the treatment of Duchenne Muscular Dystrophy (DMD).

intervention: Stem Cells

mechanism of action: Stem cell therapy to promote cellular regeneration

results: https://clinicaltrials.gov/ct2/show/results/NCT03067831

last updated: November 18, 2019

start date: September 2015

estimated completion: December 2019

phase of development: Phase 1/Phase 2

size / enrollment: 20

study description:
Duchenne muscular dystrophy (DMD) is a genetically determined X-linked disease. The manifestation of muscle weakness typically starts around the age of 4-5 in males and deteriorates fast. Typically muscle loss occurs first in the upper legs and pelvis followed by muscles of the upper arms. It is caused by a mutation in the gene for the protein dystrophin. Dystrophin is crucial to maintain the muscle fiber cell membrane.
Currently, there is no cure for muscular dystrophy. Corrective surgery, braces, and physical therapy may help with some of the symptoms. Assisted ventilation might be required in patients with weakness of breathing muscles. Medications prescribed include steroids to slow muscle degeneration, anti-convulsants to control seizures and muscle activity, and immunosuppressants to delay damage to muscle cells.
For decades, research has been conducted to find an effective therapy for Duchenne muscular dystrophy (DMD). Stem cell based therapy is considered to be one of the most promising methods for treating muscular dystrophies.
Stem cell based therapies for the treatment of Duchenne muscular dystrophy (DMD) can proceed via two strategies. The first is autologous stem cell transfer involving cells from a patient with Duchenne muscular dystrophy (DMD) that are genetically altered in vitro to restore dystrophin expression and are subsequently re-implanted. The second is allogenic stem cell transfer, containing cells from an individual with functional dystrophin, which are transplanted into a dystrophic patient.
Herein, the investigators describe a method for the treatment of Duchenne muscular dystrophy (DMD) using autologous bone marrow derived specific populations of stem cells and mesenchymal stem cells transplanted in patients with Duchenne muscular dystrophy (DMD).

primary outcomes:

• Improvement in muscle strength using Kinetics Muscle testing or MMT [ Time Frame: 12 months ]

secondary outcomes:

• Brooke and Vignos Scale [ Time Frame: 12 months ]

inclusion criteria:

exclusion criteria:
• Respiratory Distress
• Acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus malignancies
• Acute medical conditions such as respiratory infections, fever, hemoglobin less than 8 bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30%
• Pregnancy or breastfeeding

sponsor: Stem Cells Arabia

contacts: Adeeb Alzoubi, PhD, 96-279-533-7575, adeebalzoubi@stemcellsarabia.net

trial center locations: Jordan